news

BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology

05.12.2022

BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference

05.10.2022

BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update

05.05.2022

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

04.03.2022

BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual Scientific Session & Expo

03.28.2022

BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

03.14.2022

BridgeBio Pharma, Inc. to Host Investor Call to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

03.11.2022

BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma’s NULIBRY™ (Fosdenopterin)

03.08.2022

Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.

03.03.2022

BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update

02.24.2022

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

01.27.2022

BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation

01.13.2022

BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study

12.27.2021

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12.10.2021

BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types

11.19.2021

BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing

11.18.2021

BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update

11.04.2021

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease

11.03.2021

BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers

10.29.2021

BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors

10.25.2021

news

Catch up on news from BridgeBio and our pipeline developments. Follow us on LinkedIn, Twitter, and Facebook to keep up with all of the latest news.

news archive

icon icon